Literature DB >> 7791120

Characterization and distribution of binding sites for a new neurotensin receptor antagonist ligand, [3H]SR 48692, in the guinea pig brain.

C Betancur1, M Canton, D Gully, G Vela, D Pélaprat, W Rostène.   

Abstract

SR 48692, a selective nonpeptide antagonist of neurotensin (NT) receptors was developed recently. In the present work we studied the binding properties of the corresponding radioligand, [3H]SR 48692, in the adult guinea pig brain. The characterization of [3H]SR 48692 binding was carried out on brain membrane preparations and the distribution of [3H]SR 48692 binding sites was determined by receptor autoradiography and compared to that of [125I]NT binding sites. In brain homogenates, [3H]SR 48692 bound to a single population of sites with a Kd of 2.19 nM and a maximal binding capacity of 1.15 pmol/mg of protein. This maximal binding capacity value was 20 times higher than that observed for [125I]NT. NT agonists were able to interact competitively with the entire population of binding sites labeled by [3H]SR 48692, but their affinities were much lower than those observed for [125I]NT. By contrast, NT antagonists exhibited similar abilities to inhibit the binding of both radioligands. The addition of unlabeled NT in saturation assays revealed a competitive inhibition of [3H]SR 48692 binding, suggesting that agonist and antagonist ligand bind to overlapping domains of the NT receptor. The autoradiographic distribution of the low-affinity NT binding sites detected by [3H]SR 48692 (96% of the receptors) was very similar to the distribution of high-affinity receptors labeled with [125I]NT (4% of the receptors). In addition, the binding of [3H]SR 48692 was insensitive to guanyl nucleotides. Taken together, these findings suggest that the binding sites detected by [3H]SR 48692 in the guinea pig brain mainly represent the uncoupled form of the NT receptor.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7791120      PMCID: PMC4826444     

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  45 in total

Review 1.  Interaction between neurotensin and dopamine in the brain. Morphofunctional and clinical evidence.

Authors:  W Rostène; A Brouard; C Dana; Y Masuo; F Agid; M Vial; A M Lhiaubet; D Pelaprat
Journal:  Ann N Y Acad Sci       Date:  1992       Impact factor: 5.691

2.  Dopaminergic control of 125I-labeled neurotensin binding site density in corticolimbic structures of the rat brain.

Authors:  D Herve; J P Tassin; J M Studler; C Dana; P Kitabgi; J P Vincent; J Glowinski; W Rostene
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

3.  Effects of neurotensin on dopamine release and metabolism in the rat striatum and nucleus accumbens: cross-validation using in vivo voltammetry and microdialysis.

Authors:  C D Blaha; A Coury; H C Fibiger; A G Phillips
Journal:  Neuroscience       Date:  1990       Impact factor: 3.590

4.  Analysis of radioligand binding experiments. A collection of computer programs for the IBM PC.

Authors:  G A McPherson
Journal:  J Pharmacol Methods       Date:  1985-11

5.  The nonpeptide neurotensin antagonist, SR 48692, used as a tool to reveal putative neurotensin receptor subtypes.

Authors:  I Dubuc; J Costentin; J P Terranova; M C Barnouin; P Soubrié; G Le Fur; W Rostène; P Kitabgi
Journal:  Br J Pharmacol       Date:  1994-06       Impact factor: 8.739

6.  Different binding epitopes on the NK1 receptor for substance P and non-peptide antagonist.

Authors:  U Gether; T E Johansen; R M Snider; J A Lowe; S Nakanishi; T W Schwartz
Journal:  Nature       Date:  1993-03-25       Impact factor: 49.962

7.  In vivo and in vitro structure-activity studies with peptide and pseudopeptide neurotensin analogs suggest the existence of distinct central neurotensin receptor subtypes.

Authors:  C Labbé-Jullié; I Dubuc; A Brouard; S Doulut; E Bourdel; D Pelaprat; J Mazella; J Martinez; W Rostène; J Costentin
Journal:  J Pharmacol Exp Ther       Date:  1994-01       Impact factor: 4.030

8.  Blockade of neurotensin binding in the rat hypothalamus and of the central action of neurotensin on the hypothalamic-pituitary-adrenal axis with non-peptide receptor antagonists.

Authors:  A Nicot; A Bérod; D Gully; W Rowe; R Quirion; E R de Kloet; W Rostène
Journal:  Neuroendocrinology       Date:  1994-06       Impact factor: 4.914

9.  Neurotensin in the human brain.

Authors:  J K Mai; J Triepel; J Metz
Journal:  Neuroscience       Date:  1987-08       Impact factor: 3.590

10.  Mesencephalic dopaminergic neurons in primary cultures express functional neurotensin receptors.

Authors:  A Brouard; D Pelaprat; C Dana; M Vial; A M Lhiaubet; W Rostène
Journal:  J Neurosci       Date:  1992-04       Impact factor: 6.167

View more
  1 in total

1.  The striatal neurotensin receptor modulates striatal and pallidal glutamate and GABA release: functional evidence for a pallidal glutamate-GABA interaction via the pallidal-subthalamic nucleus loop.

Authors:  L Ferraro; T Antonelli; W T O'Connor; K Fuxe; P Soubrié; S Tanganelli
Journal:  J Neurosci       Date:  1998-09-01       Impact factor: 6.167

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.